Galecto Inc

GLTO13 Dec 2024
Healthcare
$5.35
-0.01 (-0.74%)
Lowest Today
$5.22
Highest Today
$5.54
Today’s Open
$5.35
Prev. Close
$5.37
52 Week High
$23.5
52 Week Low
$5.22
To Invest in Galecto Inc

Galecto Inc

Healthcare
GLTO13 Dec 2024
-0.01 (-0.74%)
1M
3M
6M
1Y
5Y
Low
$5.22
Day’s Range
High
$5.54
5.22
52 Week Low
$5.22
52-Week Range
52 Week High
$23.5
5.22
1 Day
-
1 Week
-
1 month return
-17.26%
3 month return
-55.62%
6 month return
+958.02%
1 Year return
+853.84%
3 Years return
+134.63%
5 Years return
-
10 Years return
-
Institutional Holdings
Novo A/S
7.59
Renaissance Technologies Corp
1.62
Vanguard Institutional Extnd Mkt Idx Tr
0.65
UBS Group AG
0.39
Fidelity Extended Market Index
0.34
Fidelity Total Market Index
0.19
Bank of America Corp
0.09

Market Status

Fundamentals
Market Cap
7.07 mln
PB Ratio
0.34
PE Ratio
0
Enterprise Value
-12.57 mln
Total Assets
38.23 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Organisation
Galecto Inc
Employees
13
Industry
Biotechnology
CEO
Dr. Hans T. Schambye M.D., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step